204 related articles for article (PubMed ID: 23552473)
1. Immunotargeting and eradication of orthotopic melanoma using a chemokine-enhanced DNA vaccine.
Igoucheva O; Grazzini M; Pidich A; Kemp DM; Larijani M; Farber M; Lorton J; Rodeck U; Alexeev V
Gene Ther; 2013 Sep; 20(9):939-48. PubMed ID: 23552473
[TBL] [Abstract][Full Text] [Related]
2. Enhancement of immunity by a DNA melanoma vaccine against TRP2 with CCL21 as an adjuvant.
Yamano T; Kaneda Y; Huang S; Hiramatsu SH; Hoon DS
Mol Ther; 2006 Jan; 13(1):194-202. PubMed ID: 16112911
[TBL] [Abstract][Full Text] [Related]
3. Vaccination with an adenoviral vector encoding the tumor antigen directly linked to invariant chain induces potent CD4(+) T-cell-independent CD8(+) T-cell-mediated tumor control.
Sorensen MR; Holst PJ; Pircher H; Christensen JP; Thomsen AR
Eur J Immunol; 2009 Oct; 39(10):2725-36. PubMed ID: 19637230
[TBL] [Abstract][Full Text] [Related]
4. Investigation on the anti-tumor efficacy by expression of GPI-anchored mIL-21 on the surface of B16F10 cells in C57BL/6 mice.
Zhao F; Dou J; Wang J; Chu L; Tang Q; Wang Y; Li Y; Cao M; Hu W; Hu K; Feng He X; Gu N
Immunobiology; 2010; 215(2):89-100. PubMed ID: 19457579
[TBL] [Abstract][Full Text] [Related]
5. [Preliminary observation on antitumor effect of HPV58 composite DNA vaccine].
Wang H; Yu JY; Li L
Zhonghua Fu Chan Ke Za Zhi; 2013 Jul; 48(7):523-7. PubMed ID: 24284225
[TBL] [Abstract][Full Text] [Related]
6. Induction of an antigen cascade by diversified subcutaneous/intratumoral vaccination is associated with antitumor responses.
Kudo-Saito C; Schlom J; Hodge JW
Clin Cancer Res; 2005 Mar; 11(6):2416-26. PubMed ID: 15788693
[TBL] [Abstract][Full Text] [Related]
7. The treatment and prevention of mouse melanoma with an oral DNA vaccine carried by attenuated Salmonella typhimurium.
Zhu X; Cai J; Huang J; Jiang X; Ren D
J Immunother; 2010 Jun; 33(5):453-60. PubMed ID: 20463603
[TBL] [Abstract][Full Text] [Related]
8. Transgenic expression of human gp100 and RANTES at specific time points for suppression of melanoma.
Aravindaram K; Yu HH; Lan CW; Wang PH; Chen YH; Chen HM; Yagita H; Yang NS
Gene Ther; 2009 Nov; 16(11):1329-39. PubMed ID: 19626052
[TBL] [Abstract][Full Text] [Related]
9. CCL21 (SLC) improves tumor protection by a DNA vaccine in a Her2/neu mouse tumor model.
Nguyen-Hoai T; Baldenhofer G; Sayed Ahmed MS; Pham-Duc M; Vu MD; Lipp M; Dörken B; Pezzutto A; Westermann J
Cancer Gene Ther; 2012 Jan; 19(1):69-76. PubMed ID: 21997231
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic efficacy of antigen-specific vaccination and toll-like receptor stimulation against established transplanted and autochthonous melanoma in mice.
Tormo D; Ferrer A; Bosch P; Gaffal E; Basner-Tschakarjan E; Wenzel J; Tüting T
Cancer Res; 2006 May; 66(10):5427-35. PubMed ID: 16707471
[TBL] [Abstract][Full Text] [Related]
11. A novel DNA vaccine constructed by heat shock protein 70 and melanoma antigen-encoding gene 3 against tumorigenesis.
Qu P; Ma JH; Zhang XM; Huang XJ; Yang XW; Yan-Fang S
Indian J Exp Biol; 2010 May; 48(5):436-43. PubMed ID: 20795360
[TBL] [Abstract][Full Text] [Related]
12. Protective immunization against melanoma by gp100 DNA-HVJ-liposome vaccine.
Zhou WZ; Kaneda Y; Huang S; Morishita R; Hoon D
Gene Ther; 1999 Oct; 6(10):1768-73. PubMed ID: 10516727
[TBL] [Abstract][Full Text] [Related]
13. Booster vaccinations against cancer are critical in prophylactic but detrimental in therapeutic settings.
Ricupito A; Grioni M; Calcinotto A; Hess Michelini R; Longhi R; Mondino A; Bellone M
Cancer Res; 2013 Jun; 73(12):3545-54. PubMed ID: 23539449
[TBL] [Abstract][Full Text] [Related]
14. Genetic vaccination against the melanocyte lineage-specific antigen gp100 induces cytotoxic T lymphocyte-mediated tumor protection.
Schreurs MW; de Boer AJ; Figdor CG; Adema GJ
Cancer Res; 1998 Jun; 58(12):2509-14. PubMed ID: 9635569
[TBL] [Abstract][Full Text] [Related]
15. Immunity against breast cancer by TERT DNA vaccine primed with chemokine CCL21.
Yamano T; Kaneda Y; Hiramatsu SH; Huang S; Tran AN; Giuliano AE; Hoon DS
Cancer Gene Ther; 2007 May; 14(5):451-9. PubMed ID: 17318199
[TBL] [Abstract][Full Text] [Related]
16. Eliciting T cell immunity against poorly immunogenic tumors by immunization with dendritic cell-tumor fusion vaccines.
Wang J; Saffold S; Cao X; Krauss J; Chen W
J Immunol; 1998 Nov; 161(10):5516-24. PubMed ID: 9820528
[TBL] [Abstract][Full Text] [Related]
17. Generation of antitumor immunity by cytotoxic T lymphocyte epitope peptide vaccination, CpG-oligodeoxynucleotide adjuvant, and CTLA-4 blockade.
Davila E; Kennedy R; Celis E
Cancer Res; 2003 Jun; 63(12):3281-8. PubMed ID: 12810660
[TBL] [Abstract][Full Text] [Related]
18. Enhanced antitumor immunity is elicited by adenovirus-mediated gene transfer of CCL21 and IL-15 in murine colon carcinomas.
Zhao DX; Li ZJ; Zhang Y; Zhang XN; Zhao KC; Li YG; Zhang MM; Yu XW; Liu MY; Li Y
Cell Immunol; 2014; 289(1-2):155-61. PubMed ID: 24838092
[TBL] [Abstract][Full Text] [Related]
19. Characterization of a novel human tumor antigen interleukin-13 receptor alpha2 chain.
Kawakami K; Terabe M; Kawakami M; Berzofsky JA; Puri RK
Cancer Res; 2006 Apr; 66(8):4434-42. PubMed ID: 16618770
[TBL] [Abstract][Full Text] [Related]
20. Comparison of recombinant adenovirus and synthetic peptide for DC-based melanoma vaccination.
Steitz J; Tormo D; Schweichel D; Tüting T
Cancer Gene Ther; 2006 Mar; 13(3):318-25. PubMed ID: 16151477
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
